• Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11.
• ALNY has a 100% technical “Buy” opinion via Barchart.
• The company boasts a robust pipeline, recent FDA approvals, and dramatic projected revenue and earnings growth for 2025.
• Analyst sentiment is mostly bullish with high price targets.

Today’s Featured Stock

Valued at $57.5 billion, Alnylam Pharmaceuticals (ALNY) is a biopharmaceutical company focused on developing novel therapeutics based on RNA interference. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas: genetic medicines, cardio-metabolic disease, and hepatic infectious disease. Its lead drug Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. 

Alnylam has received FDA approval for several of its other therapeutics. 

What I’m Watching

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. ALNY checks those boxes. Since the Trend Seeker signaled a buy on July 23, the stock has gained 34.04%.

ALNY Price vs. Daily Moving Averages:

Barchart Technical Indicators for Alnylam

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

Alnylam shares hit a new all-time high on Aug. 11, touching $442.61 in morning trading.

• Alnylam has a Weighted Alpha of +88.62.
• ALNY has an 100% “Buy” opinion from Barchart.
• The stock has gained 63.5% over the past year.
• ALNY has its Trend Seeker “Buy” signal intact.
• Alnylam is trading above its 20-, 50-, and 100-day moving averages.
• The stock made 12 new highs and gained 39.9% in the last month.
• Relative Strength Index (RSI) is at 88.91%.
• There’s a technical support level around $431.27.

Don’t Forget the Fundamentals

• $57.5 billion market capitalization.
• Revenue is projected to increase 55.73% this year and another 38.02% next year.
• After reporting a loss per share of $2.18 in 2024, Alnylam is projected to turn profitable and report massively improved earnings per share of $0.85. For 2026, the company is projected to increase earnings an additional 134.79%. 

Analyst and Investor Sentiment on Alnylam

I don’t buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it’s hard to make money swimming against the tide.

It looks like Wall Street analysts are bullish on ALNY, but Morningstar is not.

• The Wall Street analysts tracked by Barchart have issued 21 “Strong Buy”, 3 “Moderate Buy,” and 6 “Hold” opinions on the stock.
• Their price targets are between $280-$570 with a consensus of $420.85.
• Although Value Line gives the stock its lowest rating, their price target is $610, or 40% above its recent price.
• CFRA’s MarketScope gives the stock a 4-star “Buy” rating with a price target of $433.
• Morningstar thinks the stock is overvalued by 65% with a fair value of $265.
• 1,176 individual investors on Motley Fool think the stock will beat the market while 267 think it won’t.
• 22,520 investors monitor the stock on Seeking Alpha, which rates the stock a “Hold.”

The Bottom Line on Alnylam Pharmaceuticals

ALNY currently has momentum and is hitting new highs. Analysts seem to think the break-even point may be in its near future.

I caution that ALNY is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies.

Today’s Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here.

Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.